ARS Pharmaceuticals announces U.S. availability of neffy

ARS Pharmaceuticals announced neffy is now available to patients and caregivers by prescription across the U.S. The U.S. Food and Drug Administration approved neffy 2 mg last month for the treatment of Type I Allergic Reactions, including anaphylaxis, in adults and children who weigh greater than or equal to30 kg. Through neffyConnect, and in partnership with online pharmacy BlinkRx, eligible commercially insured patients will pay $25 for two single-use neffy devices through a co-pay savings program. For patients without insurance coverage, or for those whose insurance plans do not yet cover neffy, ARS Pharmaceuticals is offering a cash price of $199 for two single-use neffy devices. neffy will be available free of charge for patients that qualify for the ARS Patient Assistance Program. Starting today, national retail pharmacies will also begin stocking neffy and a $25 co-pay savings card can be downloaded at neffy.com for use at pharmacies by eligible patients.